PERRINO, MATTEO ROMUALDO ANANIA
PERRINO, MATTEO ROMUALDO ANANIA
Universita' degli Studi di MILANO
Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group
2022 G. Antonarelli, C. Corti, P.A. Zucali, M. Perrino, S. Manglaviti, G. Lo Russo, G.M. Varano, P. Salvini, G. Curigliano, C. Catania, F. Conforti, T. De Pas
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
2022 F. Conforti, P.A. Zucali, L. Pala, C. Catania, V. Bagnardi, I. Sala, P. Della Vigna, M. Perrino, P. Zagami, C. Corti, S. Stucchi, M. Barberis, E. Guerini-Rocco, B. Di Venosa, F. De Vincenzo, N. Cordua, A. Santoro, G. Giaccone, T.M. De Pas
Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease
2014 L. Toschi, G. Finocchiaro, T.T. Nguyen, M.C. Skokan, L. Giordano, L. Gianoncelli, M. Perrino, L. Siracusano, L. Di Tommaso, M. Infante, M. Alloisio, M. Roncalli, M. Scorsetti, P.A. Jänne, A. Santoro, M. Varella Garcia
Clinical and molecular analyses of thyroid cancer in patients treated for benign diseases
2013 S. De Leo, M. Perrino, S. Badiali, S. Rossi, V. Cirello,C. Colombo, D. Tosi, G. Cantoni, L. Poggi, G. Bulfamante, P. Beck-Peccoz, L. Vicentini, L. Fugazzola